Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection

Journal of Parasitology

Volumn 96, Issue 5, 2010, Pages 929-936

  Henriquez, F L ^a   Campbell, S A ^a,b   Roberts, C W ^a,c   Mullen, A B ^a,c   Burchmore, R ^a,d   Carter, K C ^a,c  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b EDINBURGH NAPIER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUTAMATE CYSTEINE LIGASE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A; NIOSOME; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PROTOZOAL VACCINE; PROTOZOON ANTIBODY;

ANTIBODY; DISEASE CONTROL; ENZYME ACTIVITY; IMMUNIZATION; LEISHMANIASIS; PROTEIN; PROTOZOAN; PUBLIC HEALTH; RECOMBINATION; SURFACTANT; VACCINATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SPLEEN CELL; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; COATED VESICLE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HAMSTER; IMMUNOLOGY; LEISHMANIASIS, VISCERAL; MESOCRICETUS; SPLEEN;

LEISHMANIA DONOVANI; MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; COATED VESICLES; CRICETINAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUTAMATE-CYSTEINE LIGASE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MESOCRICETUS; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; RECOMBINANT FUSION PROTEINS; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 77958193888     PISSN: 00223395     EISSN: 19372345     Source Type: Journal    
DOI: 10.1645/GE-2360.1     Document Type: Article

References (18)

1. ALEXANDER, J., AND E. MCFARLANE. 2008. Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent? Microbes and Infection. 10: 953-959.
2. ALVAR, J., P. APARICIO, A. ASEFFA, M. DEN BOER, C. CAÑAVATE, J. P. DEDET, L.GRADONI, R. TER HORST, R. LÓPEZ-VÉLEZ, AND J. MORENO. 2008. The relationship between leishmaniasis and AIDS: The second 10 years. Clinical Microbiology Reviews 21: 334-359.
3. BANDUWARDENE R., A. B. MULLEN, AND K. C. CARTER. 1997. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations. International Journal of Immunopharmacalogy 19: 195-203.
4. BHOWMICK, S., AND N. ALI. 2009. Identification of novel Leishmania donovani antigens that help define correlates of vaccinemediated protection in visceral leishmaniasis. PLoS ONE 4: e5820.
5. CARTER, K. C., F. L. HENRIQUEZ, S. A. CAMPBELL, C. W. ROBERTS, A. NOK, A. B. MULLEN, AND E. MCFARLANE. 2007. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine 25: 4502-4509.
6. CHAPPUIS, F., S. SUNDAR, A.HAILU, H.GHALIB, S.RIJAL, R.W. PEELING, J. ALVAR, AND M. BOELAERT. 2007. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nature Reviews Microbiology 5: 873-882.
7. DE OLIVEIRA, C. I., I. P. NASCIMENTO, A. BARRAL, M. SOTO, AND M. BARRAL-NETTO. 2009. Challenges and perspectives in vaccination against leishmaniasis. Parasitology International 58: 319-324.
8. DINARELLO, C. A. 2004. Infection, fever, and exogenous and endogenous pyrogens: Some concepts have changed. Journal of Endotoxin Research 10: 201-222.
9. DUMONTEIL, E. 2007. DNA Vaccines against protozoan parasites: Advances and challenges. Journal of Biomedicine & Biotechnology 2007: 905-920.
10. FERRO, V. A., R. COSTA, K. C. CARTER, M. J.HARVEY, M. M.WATERSTON, A. B. MULLEN, C. MATSCHKE, J. F. MANN, A. COLSTON, AND W. H. STIMSON. 2004. Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy. Vaccine 22: 1024-1031.
11. GANGULY, S., N. K. DAS, M. PANJA, S. PAL, D.MODAK, M. RAHAMAN, S. MALLIK, S. K. GUHA, N. PRAMANIK, R. GOSWAMI et al. 2008. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. Journal of Infectious Diseases 197: 1762-1771.
12. GHALIB, H., AND F. MODABBER. 2007. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biology and Disease 17: 6-7.
13. MAGALHÃES, P. O., A. M. LOPES, P.G.MAZZOLA, C.RANGEL-YAGUI, T. C. PENNA, AND A. PESSOA, JR. 2007. Methods of endotoxin removal from biological preparations: A review. Journal of Pharmacy & Pharmaceutical Sciences 10: 388-404.
14. NYLÉN, S., AND D. SACKS. 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends in Immunology 28: 378-384.
15. O'HAGAN, D. T., AND E. DE GREGORIA. 2009. The path to a successful vaccine adjuvant: "The long and winding road." Drug Discovery Today 14: 541-551.
16. PALATNIK-DE-SOUSA, C. B. 2008. Vaccines for leishmaniasis in the forecoming 25 years. Vaccine 26: 1709-1724.
17. PERRIE, Y., A. R. MOHAMMED, D. J. KIRBY, S. E. MCNEIL, AND V. W. BRAMWELL. 2008. Vaccine adjuvant systems: Enhancing the efficacy of sub-unit protein antigens. International Journal of Pharmaceutics 64: 272-280.
18. QORONFLEH, M. W., L. K. HESTERBERG, AND M. B. SEEFELDT. 2007. Confronting high-throughput protein refolding using high pressure and solution screens. Protein Expression and Purification 55: 209-224.